{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:19Z","timestamp":1792218619963,"version":"4.4.0"},"reference-count":99,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Irinotecan, a topoisomerase I inhibitor, is available as both non\u2010pegylated and pegylated formulations. The non\u2010pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy. However, it is also used off\u2010label across a range of gastrointestinal malignancies and in rare malignancies such as glioblastoma and sarcomas. The pegylated formulation is licensed for use as combination therapy in adult patients with metastatic pancreatic adenocarcinoma. Irinotecan is hydrolysed to its active metabolite, SN\u201038, which is predominantly inactivated by the enzyme uridine diphosphate glucuronosyltransferase UGT1A1. UGT1A1 is encoded by the gene\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    , which is polymorphically expressed, with allele frequencies varying across populations. Poor metabolizers carry two variants that reduce UGT1A1 enzyme expression or activity, leading to increased risk of irinotecan toxicity. Any patient who is about to be prescribed irinotecan for an epithelial malignancy should have pharmacogenetic testing, to identify clinically relevant\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    variants, where testing is available. Irinotecan dose should be reduced by 30% at Cycle 1 treatment in poor metabolizers for all indications, with doses titrated thereafter based on tolerability and neutrophil counts. The lack of evidence precludes us from making any recommendation for rare malignancies such as sarcomas. Our guideline is consistent with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk\u2013benefit profile, ensuring that therapy is optimized to maximize benefits while minimizing potential harms.\n                  <\/jats:p>","DOI":"10.1002\/bcp.70659","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:04:20Z","timestamp":1782983060000},"page":"2986-3001","source":"Crossref","is-referenced-by-count":2,"title":["<i>UGT1A1<\/i>\n                    genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI\u2010PGx)"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1781-4011","authenticated-orcid":false,"given":"Dharmisha","family":"Chauhan","sequence":"first","affiliation":[{"name":"North Thames Genomic Medicine Service Alliance, Great Ormond Street Hospital for Children NHS Foundation Trust  London UK"},{"name":"Royal Marsden NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-3832","authenticated-orcid":false,"given":"Cinzia","family":"Dello Russo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"Department of Translational Medicine and Surgery, Section of Pharmacology Universit\u00e0 Cattolica del Sacro Cuore\u2014Fondazione Policlinico Universitario A. Gemelli, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6480-3779","authenticated-orcid":false,"given":"Jack","family":"Thompson","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":false,"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation North Wales Medical School Bangor University  Bangor UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Payne","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Faculty of Biology University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsakiroglou","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ross","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Keen","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust  Manchester UK"},{"name":"Division of Evolution, Infection and Genomics University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-1641","authenticated-orcid":false,"given":"Sophie","family":"Harding","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff and Vale University Health Board  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Lau","sequence":"additional","affiliation":[{"name":"Swansea Bay University Health Board  Swansea UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Braun","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Agarwal","sequence":"additional","affiliation":[{"name":"University Hospitals of Northamptonshire  Northampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Adams","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre Velindre University NHS Trust  Cardiff UK"},{"name":"Cardiff University  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rolf","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Al\u2010Sheikhli","sequence":"additional","affiliation":[{"name":"Dorset County Hospital NHS Foundation Trust, Dorchester  Dorset UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hammond","sequence":"additional","affiliation":[{"name":"Mount Alvernia Hospital  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Roberts","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre Velindre University NHS Trust  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Cairns","sequence":"additional","affiliation":[{"name":"Western Health and Social Care Trust  Londonderry UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Heggarty","sequence":"additional","affiliation":[{"name":"Belfast Health and Social Care Trust  Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Graham","sequence":"additional","affiliation":[{"name":"West of Scotland Cancer Network  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Mencel","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"Wolfson Centre for Personalised Medicine, Centre for Drug Safety Science University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104528"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010024\u201002868\u20104"},{"key":"e_1_2_17_5_1","unstructured":"National Institute for Health and Care Excellence.NICE pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA 440). 26 Apr2017.https:\/\/www.nice.org.uk\/guidance\/ta440[Accessed 7th October 2025]."},{"issue":"16","key":"e_1_2_17_6_1","first-page":"4187","article-title":"Intracellular roles of SN\u201038, a metabolite of the camptothecin derivative CPT\u201011, in the antitumor effect of CPT\u201011","volume":"51","author":"Kawato Y","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199733040\u201000001"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163\u20107258(95)02009\u20108"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.608"},{"issue":"16","key":"e_1_2_17_10_1","first-page":"3752","article-title":"Involvement of beta\u2010glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT\u201011) in rats","volume":"56","author":"Takasuna K","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i6.426"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200009283431302"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200023040\u201000001"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1303"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431\u2010022\u201001243\u20102"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500171"},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.09.014"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010023\u201006045\u20100"},{"key":"e_1_2_17_19_1","unstructured":"CPIC.Clinical Pharmacogenetics Implementation Consortium gene\u2010specific information tables for UGT1A1.https:\/\/www.clinpgx.org\/page\/ugt1a1RefMaterials[Accessed 30th October 2025]."},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199511023331802"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000024"},{"key":"e_1_2_17_22_1","unstructured":"Dean L.Irinotecan therapy and UGT1A1 genotype. 27 May 2015.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK294473\/[Accessed 7th October 2025]."},{"key":"e_1_2_17_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.10"},{"key":"e_1_2_17_24_1","unstructured":"CAMPTOSAR (irinotecan) injection.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020571s048lbl.pdf[Accessed 7th October 2025]."},{"key":"e_1_2_17_25_1","unstructured":"Laval University.UGT1A1 and common exons allele nomenclature.https:\/\/www.pharmacogenomics.pha.ulaval.ca\/wp-content\/uploads\/2015\/04\/UGT1A1-allele-nomenclature.html[Accessed 7th October 2025]."},{"key":"e_1_2_17_26_1","unstructured":"CliniPGx.Clinical Pharmacogenetic (ClinPGx) Database.https:\/\/www.clinpgx.org\/gene\/PA420\/haplotype[Accessed 8th October 2025]."},{"key":"e_1_2_17_27_1","unstructured":"gnomAD.Genome Aggregation Database (gnomAD).https:\/\/gnomad.broadinstitute.org\/[Accessed 5th July 2025]."},{"key":"e_1_2_17_28_1","unstructured":"Pfizer Limited.CAMPTO 20\u2009mg\/mL concentrate for solution for infusion (100\u2009mg & 300\u2009mg presentation).https:\/\/www.medicines.org.uk\/emc\/product\/9083\/smpc[Accessed 7th October 2025]."},{"key":"e_1_2_17_29_1","unstructured":"Servier Laboratories Limited.ONIVYDE pegylated liposomal 4.3\u2009mg\/mL concentrate for dispersion for infusion.https:\/\/www.medicines.org.uk\/emc\/product\/9200\/smpc[Accessed 7th October 2025]."},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13028"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.049"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201010\u20101122"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm115"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010017\u20103306\u20109"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/1354750x.2013.867534"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17210"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010014\u20102405\u20100"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0b013e328014341f"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2015.11.002"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae122"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13277"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1563566"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622416.2024.2385289"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/po\u201025\u201000086"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020204"},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15092"},{"key":"e_1_2_17_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147\u2010022\u201002186\u2010w"},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241236658"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.009"},{"key":"e_1_2_17_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.23"},{"key":"e_1_2_17_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29031"},{"key":"e_1_2_17_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00458"},{"key":"e_1_2_17_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00124"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201022\u20103546"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30005"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13569\u2010015\u20100035\u2010x"},{"key":"e_1_2_17_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.10.2301"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1215\/15228517\u20102008\u2010075"},{"key":"e_1_2_17_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010009\u20100103\u20102"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010017\u20103247\u20103"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.5400"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13807"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605776"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201006\u20102290"},{"key":"e_1_2_17_65_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i45.6635"},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101629"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13704"},{"key":"e_1_2_17_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70083"},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479\u20107364\u20104\u20104\u2010238"},{"issue":"2","key":"e_1_2_17_70_1","first-page":"249","article-title":"Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia","volume":"136","author":"Teh LK","year":"2012","journal-title":"Indian J Med Res"},{"key":"e_1_2_17_71_1","unstructured":"Ross P Marinaki T Keen J Pirmohamed M.Personalised medicine approach for fluoropyrimidine\u2010based therapies.2024.https:\/\/www.uksactboard.org\/publications[Accessed 8th October 2025]."},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.7011"},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/gim.0b013e31818efd77"},{"key":"e_1_2_17_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12117"},{"key":"e_1_2_17_75_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.68"},{"key":"e_1_2_17_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.16"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2017.01.005"},{"key":"e_1_2_17_78_1","unstructured":"ClinPGx.Annotation of RNPGx guideline for irinotecan and UGT1A1.https:\/\/www.clinpgx.org\/chemical\/PA450085\/guidelineAnnotation\/PA166127626[Accessed 10th November 2025]."},{"key":"e_1_2_17_79_1","doi-asserted-by":"publisher","DOI":"10.1684\/bdc.2014.1933"},{"key":"e_1_2_17_80_1","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.229.107"},{"key":"e_1_2_17_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.34"},{"key":"e_1_2_17_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100507"},{"key":"e_1_2_17_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1049"},{"key":"e_1_2_17_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)01841\u20104"},{"key":"e_1_2_17_85_1","unstructured":"Latiano T.P. Tiseo M. Pietrantonio F. Re M.D. Clementi E. Toffoli G.Raccomandazionianalisi farmacogenetiche UGT1A1 E irinotecano. Joint Working Group of the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF). In:2024."},{"key":"e_1_2_17_86_1","unstructured":"ClinPGx.Annotation of AIOM guideline for irinotecan and UGT1A1.https:\/\/www.clinpgx.org\/chemical\/PA450085\/guidelineAnnotation\/PA166312821[Accessed 1st December 2025]."},{"key":"e_1_2_17_87_1","unstructured":"HughesDJonesAFargherEAGollinsSStuartNWagstaffJCost effectiveness of pre\u2010prescription pharmacogenetic testing for irinotecan2012https:\/\/pure.bangor.ac.uk\/admin\/files\/82955309\/NISCHR_final_report_irinotecan_pharmacogenetics_1_.pdf"},{"key":"e_1_2_17_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.116"},{"key":"e_1_2_17_89_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.5.539"},{"key":"e_1_2_17_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24428"},{"key":"e_1_2_17_91_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186x.2015.1053983"},{"key":"e_1_2_17_92_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102018\u20100138"},{"key":"e_1_2_17_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.07.008"},{"key":"e_1_2_17_94_1","unstructured":"ClinPGx.Annotation of FDA label for irinotecan and UGT1A1.https:\/\/www.clinpgx.org\/labelAnnotation\/PA166104831[Accessed 1st December 2025]."},{"key":"e_1_2_17_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.269"},{"key":"e_1_2_17_96_1","unstructured":"ClinPGx.UGT1A1 drug label annotations.https:\/\/www.clinpgx.org\/gene\/PA420\/labelAnnotation[Accessed 10th April 2026]."},{"key":"e_1_2_17_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20100670"},{"key":"e_1_2_17_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70060"},{"key":"e_1_2_17_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70462"},{"key":"e_1_2_17_100_1","unstructured":"Gilead Sciences Ltd.Trodelvy 180\u2009mg powder for concentrate for solution for infusion. 25\/09\/2025.https:\/\/www.medicines.org.uk\/emc\/product\/12880\/smpc[Accessed 8th October 2025]."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70659","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:38:20Z","timestamp":1787819900000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/bcp.70659"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70659","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}